- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05731700
CVT-ISR First in Human Trial for Coronary In-Stent Restenosis
Everolimus-Coated Percutaneous Transluminal Coronary Angioplasty Catheter First in Human Clinical Investigation: A Clinical Evaluation in the Treatment of Subjects With In-Stent Restenosis of Previously-treated Coronary Artery Lesions
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The CVT-ISR Trial is a prospective, multi-center, open, single arm study enrolling subjects with visually estimated nominal vessel diameter ≥2.0 mm and ≤3.5mm and lesion length ≤24 mm receiving up to two (2) CVT Everolimus CVT EVE-PTCA Catheters.
An angiographic follow up, in combination with either Intravascular Ultrasound (IVUS) or Optical Coherence Tomography (OCT), follow-up, will be carried out in a subset of 25 patients at 180 days following the index procedure.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Grenoble, France, 38000
- Groupe Hospitalier Mutualiste de Grenoble
-
Nantes, France, 44000
- L'Hôpital privé du Confluent
-
Toulouse, France, 31300
- Clinique Pasteur
-
-
-
-
-
Tbilisi, Georgia, 0159
- Tbilisi Heart and Vascular Clinic
-
Tbilisi, Georgia
- Georgian Israeli Research Medical Centre Helsicore
-
-
-
-
-
Vilnius, Lithuania, 08410
- Vilniaus universiteto ligoninė Santaros klinikos
-
-
-
-
-
Barcelona, Spain, 08036
- Hospital Clinic de Barcelona
-
Madrid, Spain, 28046
- Hospital Universitario La Paz
-
Madrid, Spain, 28006
- Hospital Universitario de La Princesa
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subject must be at least 18 years of age.
- Subject or his/her legally authorized representative provides written informed consent prior to any clinical investigation related procedure, as approved by the appropriate Ethics Committee of the respective clinical site.
- Subject must agree to undergo all clinical investigation plan-required follow-up visits, angiograms, IVUS/OCT and examinations.
Angiographic Inclusion Criteria
- Target lesion must be located within a stent (bare metal or drug eluting) placed in a native epicardial coronary vessel with visually estimated nominal vessel diameter of ≥2.0mm and ≤3.5mm.
- Target lesion must measure ≤24 mm in length by visual estimation.
- The target lesion must be with a visually estimated stenosis of ≥50% and < 100% with a TIMI flow of ≥1.
- Non-clinical investigation, percutaneous intervention for lesions in a non-target vessel is allowed if done ≥90 days prior to or planned to be done 6 months after the index procedure.
- Non-clinical investigation, percutaneous intervention for lesions in the target vessel is allowed if planned to be done 6 months after the index procedure.
Exclusion Criteria:
- Subject with known diagnosis of acute myocardial infarction (AMI) within 30 days preceding the index procedure and CK-MB or troponin have not returned within normal limits at the time of procedure.
- The subject is currently experiencing clinical symptoms consistent with AMI.
- Subject has current unstable arrhythmia.
- Subject has a known left ventricular ejection fraction (LVEF) <25%.
- Subject has a known hypersensitivity or contraindication to aspirin, both heparin and bivalirudin, both clopidogrel and ticlopidine and structurally related compounds, everolimus, or contrast sensitivity that cannot be adequately pre-medicated.
- Subject has known renal insufficiency (e.g., serum creatinine > 2.5 mg/dL, (i.e. 221 µmol/L) within 7 days prior to index procedure or creatinine clearance <30mL/min or subject is on dialysis.
- Subject has a history of bleeding diathesis or coagulopathy or will refuse blood transfusions.
- Subject has had a cerebrovascular accident (CVA) or transient ischemic neurological attack (TIA) within the past six months.
- Subject has other medical illness (e.g., cancer or congestive heart failure) or known history of substance abuse (alcohol, cocaine, heroin etc.) that may cause non-compliance with the clinical investigation plan, confound the data interpretation or is associated with a limited life expectancy (i.e., less than one year).
- Subject is already participating in another clinical investigation that has not yet reached its primary endpoint.
- Subject is not, in the opinion of the investigator, an acceptable candidate to participate in the study.
- In-stent lesions for stent are located within an arterial or saphenous vein graft or stent used to treat a previous ISR.
- The target vessel contains visible thrombus.
- Pregnant or lactating females.
- Restenosis is present in a stent previously deployed in the left main coronary artery.
- Subjects who are not candidates for coronary bypass surgery.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Drug eluting balloon
Treatment of a single in-stent restenosis coronary artery lesion with drug eluting balloon
|
PCI of in-stent restenosis
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Freedom from target lesion failure rate
Time Frame: 6 months post-index procedure
|
Composite rate of cardiovascular death, target vessel myocardial infarction and clinically-driven target lesion revascularization (TLR).
|
6 months post-index procedure
|
In-stent late lumen loss
Time Frame: 180 days post-procedure
|
In-stent late lumen loss (LLL)
|
180 days post-procedure
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Target lesion failure
Time Frame: one year post-procedure
|
Composite rate of cardiovascular death, target vessel myocardial infarction and clinically-driven target lesion revascularization (TLR).
|
one year post-procedure
|
Target vessel failure
Time Frame: one year post-procedure
|
Composite rate of cardiovascular death, target vessel myocardial infarction, and target vessel revascularization (TVR).
|
one year post-procedure
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- TP1125
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on In-stent Restenosis
-
Assiut UniversityNot yet recruiting
-
Luzerner KantonsspitalUnknown
-
Fundación Médica para la Investigación y Desarrollo...Abbott Medical Devices; Hospital San Carlos, Madrid; B.Braun Surgical SAUnknown
-
Cordis CorporationCompletedIn-Stent RestenosisUnited States
-
Boston Scientific CorporationActive, not recruiting
-
Klinikum CoburgUnknown
-
Seoul National University HospitalUnknownIn-stent Restenosis LesionKorea, Republic of
-
Midwest Cardiovascular Research FoundationCompletedFemoropopliteal In-stent RestenosisUnited States
-
Spanish Society of CardiologyAbbott Medical Devices; Terumo Medical Corporation; Fundación de Investigación... and other collaboratorsUnknownCoronary In-stent RestenosisSpain
-
Spectranetics CorporationYale UniversityWithdrawnFemoropopliteal In-Stent RestenosisColombia
Clinical Trials on Drug Eluting Balloon
-
Henan Institute of Cardiovascular EpidemiologyRecruiting
-
Fatebenefratelli and Ophthalmic HospitalCompletedCardiovascular Diseases
-
ZhuHai Cardionovum Medical Device Co., Ltd.R&G Pharma Studies Co.,Ltd.Completed
-
Bon-Kwon KooSeoul St. Mary's Hospital; Chonnam National University Hospital; Seoul National... and other collaboratorsRecruitingCoronary Artery Disease | Multi Vessel Coronary Artery DiseaseKorea, Republic of
-
Second Affiliated Hospital, School of Medicine,...Unknown
-
Second Affiliated Hospital, School of Medicine,...Ningbo No. 1 HospitalUnknown
-
Academisch Medisch Centrum - Universiteit van Amsterdam...RecruitingCoronary Artery DiseaseNetherlands
-
King Faisal Specialist Hospital & Research CenterUnknownStenosis of Arteriovenous Dialysis FistulaSaudi Arabia
-
Ospedale Santa Maria GorettiWithdrawn
-
Cordis CorporationCompletedPeripheral Arterial DiseasesGermany